Literature DB >> 2157692

Philadelphia chromosome-positive chronic myelogenous leukemia with deleted fusion of BCR and ABL genes.

K Ohyashiki1, J H Ohyashiki, H Iwabuchi, T Tauchi, A Iwabuchi, K Toyama.   

Abstract

In the great majority of patients with chronic myelogenous leukemia (CML) the reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), resulting in the Philadelphia (Ph) chromosome produces fusion DNA sequences consisting of the 5' part of the major breakpoint cluster region-1 (M-BCR-1) and the ABL protooncogene which encodes for the P210BCR-ABL phosphoprotein with tyrosine kinase activity implicated in the pathogenesis of CML. Molecular analysis was performed on 25 patients with Ph-positive CML using 2 breakpoint cluster region (bcr) probes within the M-BCR-1 DNA sequences, and two of them did not contain either detectable rearranged DNA homologous to the 5' side bcr probe or ABL-related fusion mRNA. The chromosomal in situ hybridization technique revealed that these two Ph-positive CML cases did not carry DNAs homologous to the 5' bcr or ABL probes on the Ph chromosome. Furthermore, one of the two Ph-positive CML cases did not show either rearranged DNA or regions homologous to the 3' bcr probe on a 9q+ chromosome, while the other CML case showed a rearrangement detected by the 3' bcr probe and transposition of the 3' bcr homologous to the 9q+ chromosome. Thus, the possibility is raised that the BCR/ABL fusion DNA has been deleted in rare CML cases, and that the deletion possibly occurred in a stepwise manner following the formation of the Ph chromosome at any stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157692      PMCID: PMC5917958          DOI: 10.1111/j.1349-7006.1990.tb02504.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  34 in total

1.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

2.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

3.  Human-fms gene is retained in acute lymphoblastic leukemia cells with del(5)(q32).

Authors:  J H Ohyashiki; K Ohyashiki; A A Sandberg; J Minowada; A J Kinniburgh
Journal:  Cancer Genet Cytogenet       Date:  1987-04

4.  Frequent and extensive deletion during the 9,22 translocation in CML.

Authors:  D W Popenoe; K Schaefer-Rego; J G Mears; A Bank; D Leibowitz
Journal:  Blood       Date:  1986-11       Impact factor: 22.113

5.  Variable breakpoints on the Philadelphia chromosome in chronic myelogenous leukemia.

Authors:  D Leibowitz; K Schaefer-Rego; D W Popenoe; J G Mears; A Bank
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

6.  Additional c-abl/bcr rearrangements in a CML patient exhibiting two ph1 chromosomes during blast crisis.

Authors:  C R Bartram; A de Klein; A Hagemeijer; F Carbonell; E Kleihauer; G Grosveld
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

7.  Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia.

Authors:  R Kurzrock; W S Kloetzer; M Talpaz; M Blick; R Walters; R B Arlinghaus; J U Gutterman
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

8.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

9.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

10.  C-abl and bcr are rearranged in a Ph1-negative CML patient.

Authors:  C R Bartram; E Kleihauer; A de Klein; G Grosveld; J R Teyssier; N Heisterkamp; J Groffen
Journal:  EMBO J       Date:  1985-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.